Literature DB >> 33484363

The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIRO uro-group.

Giulia Marvaso1,2, Luca Nicosia3, Annamaria Vinciguerra4, Paolo Borghetti5, Luca Eolo Trodella6, Giulio Francolini7, Giorgia Timon8, Fabio Matrone9, Lucia Ognibene10, Ciro Franzese11,12, Barbara Alicja Jereczek-Fossa13,14, Stefano Arcangeli15.   

Abstract

Radiotherapy (RT) is rarely used in the palliative management of muscle-invasive bladder cancer (MIBC). This survey aims to explore current care patterns within the Italian Radiation Oncologist community on this topic. In 2020, the uro-oncological study group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) conducted a survey evaluating the RT role in advanced MIBC. An electronic questionnaire was administered online to the society members asking for: general considerations, patients' selection, and aim of the treatment, RT schedule and practical consideration, past and future perspective. Sixty-one questionnaires were returned (33% response rate). Most responders (62.30%) declared to work in a Center with a multidisciplinary uro-oncological team, and 8.20% to evaluate more than 20 patients with MIBC/year for palliative RT. Elderly patients were the most frequently evaluated (46.7%) and life expectancy was the most common selection criteria (44.60%). Thirty Gy in 10 fractions (58.9%), whole bladder as GTV (62.5%), PTV isotropic margins of 1.5-2 cm (44.6%) and IMRT/VMAT technique (58.14%) were the most common treatment choices. Patients amenable for bladder palliative RT were most commonly referred by the urologist (43.86%) or the multidisciplinary team (38%). The reported main reasons for the low involvement of radiation oncologist in the management of MIBC patients were low attention to the palliative setting in bladder cancer (37.5%); radiation oncologist not involved in the management of these patients (32.1%); cases not discussed in the multidisciplinary board (26.8%). This survey illustrated the current use of palliative RT for patients with advanced MIBC in Italy and suggested the need for a greater involvement of radiation oncologists in their management.

Entities:  

Keywords:  AIRO; Bladder cancer; Palliative radiotherapy; Survey

Year:  2021        PMID: 33484363     DOI: 10.1007/s12032-021-01455-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  11 in total

1.  Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years.

Authors:  Richard C Khor; Mathias Bressel; Jo Tedesco; Keen Hun Tai; David L Ball; Gillian M Duchesne; Helen Farrugia; Wai Kuan Yip; Farshad Foroudi
Journal:  Med J Aust       Date:  2015-02-16       Impact factor: 7.738

2.  A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09.

Authors:  G M Duchesne; J J Bolger; G O Griffiths; J Trevor Roberts; J D Graham; P J Hoskin; S D Fossâ; B M Uscinska; M K Parmar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-05-01       Impact factor: 7.038

3.  Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy.

Authors:  Barbara Alicja Jereczek-Fossa; Renzo Colombo; Tiziana Magnani; Cristiana Fodor; Marianna Alessandra Gerardi; Paolo Antognoni; Lucia Barsacchi; Nice Bedini; Stefano Bracelli; Alberto Buffoli; Emanuela Cagna; Gianpiero Catalano; Stefania Gottardo; Corrado Italia; Giovanni Battista Ivaldi; Stefano Masciullo; Anna Merlotti; Enrico Sarti; Marta Scorsetti; Flavia Serafini; Mariasole Toninelli; Elisabetta Vitali; Riccardo Valdagni; Elisa Villa; Dario Zerini; Ottavio De Cobelli; Roberto Orecchia
Journal:  Tumori       Date:  2015-03-05       Impact factor: 2.098

4.  Palliative radiation therapy in bladder cancer: a matter of dose, techniques and patients' selection.

Authors:  Barbara A Jereczek-Fossa; Giulia Marvaso
Journal:  Ann Palliat Med       Date:  2019-11

5.  Palliative Radiation Therapy in Bladder Cancer-Importance of Patient Selection: A Retrospective Multicenter Study.

Authors:  Amin Ali; Yee Pei Song; Shaveta Mehta; Hitesh Mistry; Ruth Conroy; Catherine Coyle; John Logue; Anna Tran; James Wylie; Tanzeel Janjua; Lisa Joseph; Joji Joseph; Ananya Choudhury
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-07-05       Impact factor: 7.038

6.  Palliative care use amongst patients with bladder cancer.

Authors:  Lee A Hugar; Samia H Lopa; Jonathan G Yabes; Justin A Yu; Robert M Turner; Mina M Fam; Liam C MacLeod; Benjamin J Davies; Angela B Smith; Bruce L Jacobs
Journal:  BJU Int       Date:  2019-03-12       Impact factor: 5.588

Review 7.  Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Betty R Ferrell; Jennifer S Temel; Sarah Temin; Erin R Alesi; Tracy A Balboni; Ethan M Basch; Janice I Firn; Judith A Paice; Jeffrey M Peppercorn; Tanyanika Phillips; Ellen L Stovall; Camilla Zimmermann; Thomas J Smith
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

Review 8.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.

Authors:  Sebastien Antoni; Jacques Ferlay; Isabelle Soerjomataram; Ariana Znaor; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

9.  EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.

Authors:  J Alfred Witjes; Marek Babjuk; Joaquim Bellmunt; H Maxim Bruins; Theo M De Reijke; Maria De Santis; Silke Gillessen; Nicholas James; Steven Maclennan; Juan Palou; Tom Powles; Maria J Ribal; Shahrokh F Shariat; Theo Van Der Kwast; Evanguelos Xylinas; Neeraj Agarwal; Tom Arends; Aristotle Bamias; Alison Birtle; Peter C Black; Bernard H Bochner; Michel Bolla; Joost L Boormans; Alberto Bossi; Alberto Briganti; Iris Brummelhuis; Max Burger; Daniel Castellano; Richard Cathomas; Arturo Chiti; Ananya Choudhury; Eva Compérat; Simon Crabb; Stephane Culine; Berardino De Bari; Willem De Blok; Pieter J L De Visschere; Karel Decaestecker; Konstantinos Dimitropoulos; Jose L Dominguez-Escrig; Stefano Fanti; Valerie Fonteyne; Mark Frydenberg; Jurgen J Futterer; Georgios Gakis; Bogdan Geavlete; Paolo Gontero; Bernhard Grubmüller; Shaista Hafeez; Donna E Hansel; Arndt Hartmann; Dickon Hayne; Ann M Henry; Virginia Hernandez; Harry Herr; Ken Herrmann; Peter Hoskin; Jorge Huguet; Barbara A Jereczek-Fossa; Rob Jones; Ashish M Kamat; Vincent Khoo; Anne E Kiltie; Susanne Krege; Sylvain Ladoire; Pedro C Lara; Annemarie Leliveld; Estefania Linares-Espinós; Vibeke Løgager; Anja Lorch; Yohann Loriot; Richard Meijer; M Carmen Mir; Marco Moschini; Hugh Mostafid; Arndt-Christian Müller; Christoph R Müller; James N'Dow; Andrea Necchi; Yann Neuzillet; Jorg R Oddens; Jan Oldenburg; Susanne Osanto; Wim J G Oyen; Luís Pacheco-Figueiredo; Helle Pappot; Manish I Patel; Bradley R Pieters; Karin Plass; Mesut Remzi; Margitta Retz; Jonathan Richenberg; Michael Rink; Florian Roghmann; Jonathan E Rosenberg; Morgan Rouprêt; Olivier Rouvière; Carl Salembier; Antti Salminen; Paul Sargos; Shomik Sengupta; Amir Sherif; Robert J Smeenk; Anita Smits; Arnulf Stenzl; George N Thalmann; Bertrand Tombal; Baris Turkbey; Susanne Vahr Lauridsen; Riccardo Valdagni; Antoine G Van Der Heijden; Hein Van Poppel; Mihai D Vartolomei; Erik Veskimäe; Antoni Vilaseca; Franklin A Vives Rivera; Thomas Wiegel; Peter Wiklund; Andrew Williams; Richard Zigeuner; Alan Horwich
Journal:  Eur Urol       Date:  2019-11-19       Impact factor: 20.096

10.  Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients.

Authors:  Lotte J Lutkenhaus; Rob M van Os; Arjan Bel; Maarten C C M Hulshof
Journal:  Radiat Oncol       Date:  2016-03-18       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.